{"prompt": "['Product: MK-3475', '26', 'Protocol/Amendment No.: 604-09', 'When considering new approaches to 1L treatment of SCLC, the dramatic initial tumor', 'response to an EP regimen seen in the large majority of SCLC patients must be', 'acknowledged; however, in nearly all cases, the tumors become resistant to this treatment.', 'Several lines of evidence support modulation of immune response in SCLC as a treatment', 'modality. The disease is associated with immunogenic effects, evidenced by the prolonged', 'survival of patients with autoantibodies (ie, anti-Hu) and neurologic paraneoplastic', 'syndromes [93]. The expression of major histocompatibility complex antigens is reduced in', \"SCLC and this may play a role in this tumor's ability to escape immune surveillance [94]\", '[95]. Interestingly, effector T-cells associated with cytolytic responses are significantly', 'higher in the peripheral blood of patients with LS-SCLC compared to those with ES-SCLC', 'and in long term disease-free survivors relative to those with recurrent disease [96]. More', 'recently, the PD-1/PD-L1 pathway, a major target of anti-tumor immunotherapy, has been', 'interrogated in SCLC utilizing immunohistochemistry (IHC) and RNA-expression to', 'evaluate the presence of PD-L1 in primary and metastatic tumor tissue as well as in TILs [97]', '[98] [99] [100] [101]. In general, 50% to 80% of tumor specimens were PD-L1-positive (ie,', '>5% of cells in the specimen expressed PD-L1). In several of these reports, when other', 'patient characteristics and treatment outcomes were considered, patients with PD-L1-positive', 'tumors had a longer OS, and higher PD-L1 expression strongly correlated with limited-stage', 'disease [99] [100] [101]. However, each of these studies utilized different types of', 'specimens, as well as antibodies.', 'Mutational burden appears to be an important determinant of response to immune checkpoint', 'inhibitors. In a recent study analyzing tumor mutational burden in NSCLC patients treated', 'with pembrolizumab, higher mutational burden was associated with improved objective', 'response, durable clinical benefit, and prolonged PFS [102]. The association between', 'response to PD-1 inhibitors, mutational burden, and tobacco exposure may have important', 'implications for SCLC, as this disease is strongly associated with smoking and has a', 'markedly elevated mutation burden, as highlighted previously.', 'KEYNOTE-028 is a Phase 1b multi-cohort study of pembrolizumab for the treatment of', 'PD-L1-positive, advanced solid tumors including SCLC. Of the 147 subjects with evaluable', 'ES-SCLC biopsy specimens who were screened, 42 (29%) had PD-L1-positive tumors and,', 'of these, 24 previously treated subjects were eventually enrolled. Notably, 21 patients', '(87.5%) were in need of third-line or greater therapy. The patients were treated with', 'pembrolizumab monotherapy for up to 2 years. Median duration of follow-up was', '9.8 months (range: 0.5 to 24.0). The ORR was 37.5% (95% confidence interval [CI] 18.8 to', '59.4) and included 1 CR and 8 PRs. Median DOR was 9.0 months (range: 1.9 to 19.9+).', 'Median PFS was 1.9 months (range: 1.7 to 5.9) and at 6 and 12 months, 29.8% and 24.8% of', 'subjects were alive and progression-free, respectively. Median OS was 9.7 months (95% CI', '4.1 to not reached); 66.0% and 35.7% of subjects were alive at 6 and 12 months,', 'respectively. Treatment-related AEs were reported for 66.0% of subjects, including', '2 subjects with Grades 3 to 5 treatment-related AEs. No new safety concerns were identified', '[103]. These results demonstrate that pembrolizumab monotherapy has meaningful anti-', 'tumor activity in heavily pre-treated subjects with PD-L1-positive SCLC. In contrast, studies', 'of topotecan as 2L treatment of SCLC demonstrated response rates of approximately 18%,', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '27', 'Protocol/Amendment No.: 604-09', 'median survival of 6 months, and duration of response of 7.5 months [104] [105] [106] [107].', 'Based on this information, incorporating pembrolizumab treatment in the 1L setting in SCLC', 'patients may lead to further improvement in outcomes.', 'Recently, Langer and colleagues reported results from KEYNOTE-021 Cohort G, a Phase 2', 'randomized', 'trial', 'comparing', 'pembrolizumab/pemetrexed/carboplatin', 'with', 'pemetrexed/carboplatin alone for the treatment of subjects with newly diagnosed NSCLC', 'regardless of PD-L1 tumor expression [108]. The ORR was 55% in the', 'pembrolizumab/pemetrexed/carboplatin arm compared with 29% in the pemetrexed/', 'carboplatin alone arm (p=0.0016), and responses occurred 1 month earlier in the', 'pembrolizumab/pemetrexed/carboplatin arm. The improvement in response was observed in', 'subjects with tumors of all PD-L1 expression levels. Progression-free survival was improved', 'for the pembrolizumab/pemetrexed/carboplatin arm compared with the pemetrexed/', 'carboplatin alone arm (13 months versus 8.9 months, respectively; p=0.0102). These data', 'indicate that pembrolizumab with chemotherapy has the potential to be an effective 1L', 'treatment for SCLC and potentially may be a regimen that can change outcomes in this', 'disease.', 'Based on the previously mentioned data and a critical need for new therapies in SCLC, we', 'are undertaking this worldwide, randomized, placebo-controlled, Phase 3, parallel group,', 'multi-site, double-blind trial of pembrolizumab plus SOC chemotherapy (EP) in subjects', 'with ES-SCLC who have not previously received systemic therapy.', '4.2.2 Rationale for Dose Selection/Regimen/Modification', '4.2.2.1 Rationale for the Dose of Pembrolizumab', 'The planned dose of pembrolizumab for this trial is 200 mg Q3W. Based on the totality of', 'data generated in the Keytruda R development program, 200 mg Q3W is the appropriate dose', 'of pembrolizumab across all indications regardless of tumor type. As outlined below, this', 'dose is justified by:', 'Clinical data from 8 randomized studies demonstrating flat dose- and exposure-', 'efficacy relationships from 2 mg/kg Q3W to 10 mg/kg every 2 weeks (Q2W),', 'Clinical data showing meaningful improvement in benefit-risk, including', 'improvement in os at 200 mg Q3W across multiple indications, and', 'Pharmacology data showing full target saturation in both systemic circulation', '(inferred from PK data) and tumor (inferred from physiologically based PK analysis', '[PBPK]) at 200 mg Q3W.', 'Among the 8 randomized dose-comparison studies, a total of 2262 subjects with melanoma', 'or NSCLC were enrolled, covering different disease settings (treatment na\u00efve, previously', 'treated, PD-L1 enriched, and all-comers) and different treatment settings (monotherapy and', 'in combination with chemotherapy). Five studies compared 2 mg/kg Q3W and 10 mg/kg', 'Q3W (KEYNOTE-001 B2, KEYNOTE-001 D, KEYNOTE-002, KEYNOTE-010, and', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}